Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.
about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesAllogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitorsAdvances in the management of myelofibrosisThe evolving treatment paradigm in myelofibrosisGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Emerging drugs for myelofibrosis.Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.Role of therapeutic apheresis and phlebotomy techniques in anaesthesia and critical care.Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosisEarly prophylactic anticoagulation for portal vein system thrombosis after splenectomy: A systematic review and meta-analysisPhiladelphia-negative chronic myeloproliferative neoplasmsRuxolitinib for myelofibrosis.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosisPhiladelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosisJAK2 inhibitors: what's the true therapeutic potential?Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?Allogeneic stem cell transplantation for myelofibrosis in 2012.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitorsPrimary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.The new landscape of therapy for myelofibrosis.Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.Definition and management of ruxolitinib treatment failure in myelofibrosis.Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.Current Challenges in Stem Cell Transplantation in Myelofibrosis.Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.Outcomes following splenectomy in patients with myeloid neoplasms.
P2860
Q26752940-7014FE19-7A00-4501-80DF-CBA01E51F97FQ26863610-C327C1E9-73E4-4A31-8A73-ED2ACCA97701Q27008072-F8371C60-16A2-4BE4-A6B6-237494CD2FB0Q27021968-943D8ED0-3ADA-4FA4-B529-E47D1E2B9743Q30276550-590FF605-8D98-4156-8F51-B5991BA360DFQ33393151-EF3A22AC-3393-478F-A43B-7CAD1FE5B3B2Q33398180-6A947443-3075-445C-971F-4B97B9777C7EQ33404574-DDC35B40-CAC7-4593-AF23-540A7AC61902Q33406990-41C445DF-2C8A-4D97-81E2-AF14B31A6839Q34122035-08FB4ADA-2C05-46C3-BA4E-6BA3E5B1CA53Q34150008-5C5071C8-4B27-4117-A06B-2D28B3B9C084Q34302770-99A1908D-AB68-47C1-B17C-F1E3E78BE210Q34625390-1ABAF942-9435-4FEC-AA36-2998469B5DCEQ34659824-CCC4C18F-C075-4FF0-9D3F-7191B2353C82Q35188877-C13B48BC-605F-4CB3-8922-4EBD6777E4EDQ35735663-E6858284-0AC0-4B95-828D-219BD2941E12Q36152283-86069DD1-5F4F-4460-8323-F6B1923781AAQ36283143-468E9D52-729F-4F97-A4D9-C605E42A5DD5Q36604028-99C33D61-59E2-4E0B-BBC0-0F0EE048100CQ36782943-881C7C2A-477F-4034-812A-B99ADD3BB73CQ36974354-D01276DE-324D-4F41-B7BD-5F8DED4DFAE3Q37034988-72E1DAAA-8E58-4830-9FC1-C08B4C30A30FQ37163590-10A7D99D-38BD-4298-B72E-45C69CCBE6B4Q37705695-D79C2C83-1B7A-4412-8191-9A2E3FA8D281Q37811430-368B1B9A-7E3C-43C7-AB09-2FC52876E37DQ37877727-898EC430-EECF-4E47-A40C-D9EF522EDCA8Q37956603-FC96573D-215D-4F12-8C5B-B7CB88F190F5Q37968531-6045539A-7F59-466C-8F97-E3A9FABBB9CFQ37998567-CA429139-DC18-4590-91FE-913D9A30B6ABQ38018908-B1C47E9D-7B0B-4266-AA50-1817BBC549EAQ38031262-9A3998D1-9FDE-4715-A725-CAC14AD1D6D0Q38076672-2F564D5E-8CD5-4030-844A-08FD19322F4AQ38150261-D60A5264-BB6F-4EB8-A71C-D5A511DCD587Q38187674-84009599-9D5E-4325-BC1D-892E18DBA7E3Q38287012-36A6CBBD-C55A-400F-BE89-1258FB0D495DQ38341625-94C61299-EFCB-46B2-B54E-56E1CBDE1368Q38569146-88CC1544-39C6-4701-A30E-9C7FABCAC7B8Q39015300-9883C7B3-9C11-4A34-B8CB-A3C6AB7F3D07Q40679370-A7C19507-2D6F-4D37-ADE9-D001329D9E5EQ41609567-B2291564-D243-46ED-8823-9B98EA066B6E
P2860
Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Palliative goals, patient sele ...... metaplasia at the Mayo Clinic.
@ast
Palliative goals, patient sele ...... metaplasia at the Mayo Clinic.
@en
type
label
Palliative goals, patient sele ...... metaplasia at the Mayo Clinic.
@ast
Palliative goals, patient sele ...... metaplasia at the Mayo Clinic.
@en
prefLabel
Palliative goals, patient sele ...... metaplasia at the Mayo Clinic.
@ast
Palliative goals, patient sele ...... metaplasia at the Mayo Clinic.
@en
P2093
P356
P1433
P1476
Palliative goals, patient sele ...... metaplasia at the Mayo Clinic.
@en
P2093
David S Nagorney
Jacob Allred
Ruben A Mesa
Susan Schwager
P304
P356
10.1002/CNCR.22021
P407
P577
2006-07-01T00:00:00Z